Welcome, Guest. Please login or register.
February 06, 2023, 04:14:10 am

Login with username, password and session length

  • Total Posts: 767741
  • Total Topics: 65596
  • Online Today: 148
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 1
Guests: 89
Total: 90


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: (Ritonavir + PF-07321332) Oral Antiviral Cuts COVID-19 Hospitalization by 89%  (Read 1520 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 20,222
  • Twitter @JimAllenDublin
    • HIV Lessons
Positive results. Still pending peer review.

POZ.com writeup:

In Short:

The Phase II/III EPIC-HR trial enrolled non-hospitalized adults with COVID-19 in North and South America, Europe, Africa and Asia who were at high risk of progressing to severe illness. They had mild to moderate symptoms starting no more than five days prior to enrollment, a positive SARS-CoV-2 test and at least one underlying condition associated with severe illness. They were randomly assigned to receive Paxlovid or a placebo twice daily for five days.

On November 5, Pfizer announced that a planned interim analysis of 1,219 participants showed an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause in people who started treatment within three days of symptom onset. Three of the 389 patients treated with Paxlovid (0.8%) were hospitalized over 28 days, compared with 27 of the 385 (7.0%) people who received the placebo. No Paxlovid recipients and seven placebo recipients died.

Among those who started treatment within five days of symptom onset, six out of 607 Paxlovid recipients (1.0%) were hospitalized, and there were no deaths. In the placebo arm, 41 out of 612 patients (6.7%) were hospitalized, and there were 10 deaths. (This larger analysis included the participants treated within three days.)

Based on these findings, which have not yet been peer-reviewed or published, an independent data and safety monitoring board, in consultation with the FDA, recommended that the trial be stopped ahead of schedule. This typically happens when early results show that a therapy is either ineffective or so effective that it would be unethical to continue giving some participants a placebo.

Treatment was generally safe and well tolerated, according to Pfizer’s press release. Rates of treatment-emergent adverse events—mostly mild—were comparable in the Paxlovid and placebo arms (19% and 21%, respectively). Side effects and drug resistance are less likely to be a concern for a medication taken for only five days, unlike drugs used for lifelong HIV treatment. In preclinical studies, it did not show evidence of mutagenesis.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP


Terms of Membership for these forums

© 2023 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.